Disruption of Nuclear Export with Selinexor or KPT-8602 Reduces Androgen Receptor Expression and Leads to Potent Anti-Tumor Activity in Preclinical Models of Androgen-Independent Prostate Cancer
Disruption of Nuclear Export with Selinexor or KPT-8602 Reduces Androgen Receptor Expression and Leads to Potent Anti-Tumor Activity in Preclinical Models of Androgen-Independent Prostate Cancer